Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5,7-Difluoro-2-indolecarboxylic acid ethyl ester, with the molecular formula C12H10F2NO2, is a synthetic intermediate in the pharmaceutical industry. It is characterized by the presence of two fluorine atoms on the indole ring, which provides unique properties and reactivity. The ethyl ester functional group makes it a versatile building block for the synthesis of more complex organic molecules. 5,7-DIFLUORO-2-INDOLECARBOXYLIC ACID ETHYL ESTER plays a crucial role in the development of pharmaceuticals and other fine chemicals.

220679-10-7

Post Buying Request

220679-10-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

220679-10-7 Usage

Uses

Used in Pharmaceutical Industry:
5,7-Difluoro-2-indolecarboxylic acid ethyl ester is used as a synthetic intermediate for the production of various drugs and biologically active compounds. Its unique properties and reactivity, due to the presence of two fluorine atoms on the indole ring, make it a valuable component in the synthesis of pharmaceuticals.
Used in Fine Chemicals Industry:
5,7-Difluoro-2-indolecarboxylic acid ethyl ester is used as a building block for the synthesis of more complex organic molecules in the fine chemicals industry. The ethyl ester functional group allows for further chemical reactions and modifications, contributing to the development of novel compounds with specific applications.

Check Digit Verification of cas no

The CAS Registry Mumber 220679-10-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,0,6,7 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 220679-10:
(8*2)+(7*2)+(6*0)+(5*6)+(4*7)+(3*9)+(2*1)+(1*0)=117
117 % 10 = 7
So 220679-10-7 is a valid CAS Registry Number.

220679-10-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 5,7-difluoro-1H-indole-2-carboxylate

1.2 Other means of identification

Product number -
Other names Ethyl 5,7-difluoroindole-2-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:220679-10-7 SDS

220679-10-7Downstream Products

220679-10-7Relevant articles and documents

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

-

, (2017/10/06)

The present invention provides compounds, compositions thereof, and methods of using the same.

HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS

-

Page/Page column 78, (2008/06/13)

Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials .

Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: Role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity

La Regina, Giuseppe,Coluccia, Antonio,Piscitelli, Francesco,Bergamini, Alberto,Sinistra, Anna,Cavazza, Antonella,Maga, Giovanni,Samuele, Alberta,Zanoli, Samantha,Novellino, Ettore,Artico, Marino,Silvestri, Romano

, p. 5034 - 5038 (2008/03/14)

Indolyl aryl sulfones bearing the 4,5-difluoro (10) or 5-chloro-4-fluoro (16) substitution pattern at the indole ring were potent inhibitors of HIV-1 WT and the NNRTI-resistant strains Y181C and K103N-Y181C. These compounds were highly effective against t

Monocyte chemoattractant protein-1 inhibitor compounds

-

, (2008/06/13)

The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R1, R2, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 220679-10-7